Abstract

Background and AimsAt present, there is a lack of simple and reliable model for early prediction of the efficacy of etanercept in the treatment of juvenile idiopathic arthritis (JIA). This study aimed to generate and validate prediction models of etanercept efficacy in patients with JIA before administration using machine learning algorithms based on electronic medical record (EMR).Materials and MethodsEMR data of 87 JIA patients treated with etanercept between January 2011 and December 2018 were collected retrospectively. The response of etanercept was evaluated by using DAS44/ESR-3 simplified standard. The stepwise forward and backward method based on information gain was applied to select features. Five machine learning algorithms, including Extreme Gradient Boosting (XGBoost), Random Forest (RF), Gradient Boosting Decision Tree (GBDT), Extremely Random Trees (ET) and Logistic Regression (LR) were used for model generation and validation with fifty-fold stratified cross-validation. EMR data of additional 14 patients were collected for external validation of the model.ResultsTender joint count (TJC), Time interval, Lymphocyte percentage (LYM), and Weight were screened out and included in the final model. The model generated by the XGBoost algorithm based on the above 4 features had the best predictive performance: sensitivity 75%, specificity 66.67%, accuracy 72.22%, AUC 79.17%, respectively.ConclusionA pre-administration model with good prediction performance for etanercept response in JIA was developed using advanced machine learning algorithms. Clinicians and pharmacists can use this simple and accurate model to predict etanercept response of JIA early and avoid treatment failure or adverse effects.

Highlights

  • Etanercept is the first and most important tumor necrosis factor (TNF) inhibitor in the treatment of MTX-resistant juvenile idiopathic arthritis (JIA)

  • The purpose of this study is to use machine learning to develop an easy-to-use and efficient prediction model based on electronic medical record (EMR), to predict the treatment response to etanercept in JIA

  • They were randomly assigned into a training set and a test set according to the ratio of 8:2

Read more

Summary

Introduction

Etanercept is the first and most important tumor necrosis factor (TNF) inhibitor in the treatment of MTX-resistant juvenile idiopathic arthritis (JIA). Like other biological agents, etanercept can early modify immune components after administration, but it still takes several months to obtain clinical efficacy. During this period, clinicians are unable to revise the main therapeutic regimen, which may delay treatment, resulting in disease progression and substantial economic burden. It is important to predict the efficacy of etanercept before administration and choose an appropriate regimen, which is beneficial to interfere with JIA progression, improve prognosis and reduce the economic burden of patients. There is a lack of simple and reliable model for early prediction of the efficacy of etanercept in the treatment of juvenile idiopathic arthritis (JIA). This study aimed to generate and validate prediction models of etanercept efficacy in patients with JIA before administration using machine learning algorithms based on electronic medical record (EMR)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call